ASCO: Bristol Myers unveils I-O triplet data in melanoma as Iovance touts 'paradigm-changing' combo result

Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches.

Related Keywords

United States ,American ,Graf Finckenstein ,Friedrich Graf Finckenstein ,Bristol Opdivo ,Merck Co ,American Society Of Clinical Oncology ,Bristol Myers Squibb ,Bristol Myer ,American Society ,Clinical Oncology ,Leerink Partners ,Fierce Pharma ,